H.R. 4525 · 119th Congress (2025–2027)
Right to FDA-Approved Medicines Act
This bill sets out statutory protections for an individual's right to access and a health care provider's right to provide medicines (i.e., drugs and biological products) approved by the Food and Drug Administration (FDA).
Generally, the bill prohibits measures that single out and impede access to FDA-approved medicines and related information. However, a party may defend against a claim that a measure violates the bill's prohibitions by demonstrating, through clear and convincing evidence, that the measure significantly advances access to FDA-approved medicines and such access cannot be advanced through less restrictive means. The bill also specifies that the prohibition preempts inconsistent state and local laws and applies in spite of other federal laws, including the Religious Freedom Restoration Act of 1993.
The Department of Justice, individuals, or health care providers may bring a lawsuit to enforce this bill, and states are not immune from suits for violations.
Show official title
To protect an individuals ability to access medicines approved by the Food and Drug Administration to protect a health care providers ability to provide such medicines, and information related to such medicines.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 4525’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Deborah K. Ross (D-NC-2)
- Cosponsors
29 cosponsors
4 original · 25 later
29 D
- Rep. Kathy Castor (D-FL-14)· Original · Jul 17, 2025
- Rep. Lizzie Fletcher (D-TX-7)· Original · Jul 17, 2025
- Rep. Kim Schrier (D-WA-8)· Original · Jul 17, 2025
- Rep. Lori Trahan (D-MA-3)· Original · Jul 17, 2025
- Rep. Bonnie Watson Coleman (D-NJ-12)· Later · Jul 21, 2025
- Rep. Steve Cohen (D-TN-9)· Later · Jul 29, 2025
- Rep. Jennifer L. McClellan (D-VA-4)· Later · Jul 29, 2025
- Rep. Nikema Williams (D-GA-5)· Later · Jul 29, 2025
- Rep. Marilyn Strickland (D-WA-10)· Later · Aug 5, 2025
- Rep. Yvette D. Clarke (D-NY-9)· Later · Aug 12, 2025
- Rep. Suzan K. DelBene (D-WA-1)· Later · Aug 12, 2025
- Rep. Mary Gay Scanlon (D-PA-5)· Later · Aug 12, 2025
- Rep. Veronica Escobar (D-TX-16)· Later · Jan 20, 2026
- Rep. Timothy M. Kennedy (D-NY-26)· Later · Jan 20, 2026
- Rep. Joyce Beatty (D-OH-3)· Later · Jan 21, 2026
- Rep. Sarah Elfreth (D-MD-3)· Later · Jan 21, 2026
- Rep. Grace Meng (D-NY-6)· Later · Jan 22, 2026
- Rep. Dina Titus (D-NV-1)· Later · Jan 22, 2026
- Rep. Ted Lieu (D-CA-36)· Later · Jan 30, 2026
- Rep. Scott H. Peters (D-CA-50)· Later · Jan 30, 2026
- Rep. Marc A. Veasey (D-TX-33)· Later · Jan 30, 2026
- Rep. Lois Frankel (D-FL-22)· Later · Feb 11, 2026
- Rep. Julie Johnson (D-TX-32)· Later · Feb 11, 2026
- Rep. Mark DeSaulnier (D-CA-10)· Later · Mar 19, 2026
- Rep. Jahana Hayes (D-CT-5)· Later · Mar 19, 2026
- Rep. April McClain Delaney (D-MD-6)· Later · Apr 27, 2026
- Rep. Angie Craig (D-MN-2)· Later · Apr 30, 2026
- Rep. Wesley Bell (D-MO-1)· Later · Jun 24, 2026
- Rep. Christopher R. Deluzio (D-PA-17)· Later · Jul 9, 2026
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Right to FDA-Approved Medicines Act
Display title, Short title · Introduced in House
To protect an individuals ability to access medicines approved by the Food and Drug Administration to protect a health care providers ability to provide such medicines, and information related to such medicines.
Official title · Introduced in House